Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy

Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought a heavy burden to society. In China, the incidence of cerebral hemorrhage is much higher than that in Europe and America, and cerebral amyloid angiopathy (CAA) is one of the causes of primary cerebral hemorrhage However, there are relatively few related studies. Therefore, the research object of this subject focuses on patients with cerebral amyloid angiopathy, in view of their high recurrence rate of vascular events and the lack of treatment methods.It aims to deeply explore the detoxification and blood stasis removal treatment plan combining traditional Chinese and Western medicine to reduce vascular events for patients.

NCT Number	NCT07250035
Lead Sponsor	Beijing Tiantan Hospital Collaborators: Dongzhimen Hospital, Beijing, The First Hospital of Jilin University, Huairou Hospital of Traditional Chinese Medicine, Weihai Wendeng District Central Hospital, Nanyang First People's Hospital of Henan province, Luohe Central Hospital, Baofeng County People's Hospital, Taoyuan County People's Hospital, Qingdao Huangdao District Central Hospital, Guantao County People's Hospital, Lushan County Hospital of Traditional Chinese Medicine, Yutian County Hospital of Traditional Chinese Medicine, Xianghe County Hospital of Traditional Chinese Medicine, Wuyuan County People's Hospital, Jiyuan Hospital of Traditional Chinese Medicine, Tonghua People's Hospital
Conditions	Cerebral Amyloid Angiopathy
Enrollment	436 participants
Start Date	2026-01-30
Primary Completion	2028-11-30 (estimated)
Study Completion	2028-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-24